IRulya Therapeutics Inc. - 8-K Filing
IRulya Therapeutics Inc. posted an updated Corporate Presentation on its website outlining pipeline progress for inhaled rapamycin (LAM-001) and provided details of anticipated clinical milestones. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $QNCX
Read the full article at SEC EDGAR
Part of the story Silence Therapeutics plc - 8-K Filing (3 articles)